ReviewCureus2025
Efficacy and Safety of High-Dose Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration (nAMD): A Systematic Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- From bench to bed: The evolution of anti-vascular endothelial growth factor therapies.Indian journal of ophthalmology · 2026Article
- Comparative Clinical and Therapeutic Landscape of Aflibercept Biosimilars (YESAFILI), High-Dose Aflibercept 8 mg (EYLEA HD), and Faricimab (VABYSMO): A Structured Narrative Review.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Age-related macular degeneration (AMD) is one of the leading causes of blindness worldwide, and so continued research into new treatment options remains a priority. No systematic review has yet analysed the effectiveness and safety of higher-dose aflibercept across the available literature. We aimed to systematically evaluate the efficacy and safety of higher-dose intravitreal aflibercept (>2 mg) on Central Retinal Thickness (CRT) and Best Corrected Visual Acuity (BCVA) in patients with neovascular AMD (nAMD). In order to achieve this, a systematic literature search was conducted in January 2025 using PubMed and Ovid MEDLINE databases. Results were screened, and inclusion criteria were applied. Studies were included if they reported outcome data for intravitreal aflibercept doses above 2 mg for the treatment of nAMD. Of 382 identified articles, eight studies met inclusion criteria, encompassing data from 903 eyes. Analysis of all studies combined revealed a statistically significant improvement at 10 months, with a 33% reduction in CRT and a 29% improvement in BCVA. Subgroup analysis suggested greater effectiveness of 8 mg compared to 3 mg doses, particularly for CRT reduction (36% at 10 months vs. 28% at 12 months). However, small sample sizes and high heterogeneity across studies, including variations in dose, injection intervals, and patient characteristics (e.g., treatment-naïve vs. treatment-resistant), limit the reliability and conclusions of these outcome findings. There was a complication rate of 1.7% for serious adverse effects. In conclusion, higher doses of aflibercept (>2 mg) are safe and effective for treating nAMD, but further research is needed to analyse the comparison of different high doses and the effect of injection frequency on outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.